Koutif Therapeutics ^Company

Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh. Their academic founders are developing an inhibitor of E3 ligase Fbxo3, which is implicated in the pathogenesis of inflammatory conditions such as neuropathic pain, bronchiolitis obliterans syndrome, irritable bowel disease, chronic obstructive pulmonary disease, rheumatoid arthritis, and acute lung injury.